Effect of aflibercept versus conbercept on neovascular age-related macular degeneration
TIAN Hong-ya
QIAN Wei-yan
MIAO Ya-xiang
ZHOU Yun-jia
XIAO Ai-ping
Abstract：Objective:To compare the effect of aflibercept with conbercept on visual acuity and adverse effects in patients with neovascular age-related macular degeneration(nAMD).Methods:One hundred and nine invalids(109 eyes)receiving intravitreal injection for nAMD in our hospital from June 2020 to February 2023 were enrolled,and divided into conbercept group(57 eyes)and aflibercept group(52 eyes)according to the drugs.Invalids were followed up for more than 3 months.Central macular thickness(CMT),best-corrected visual acuity(BCVA),vascular leakage of choroidal neovascularisation(CNV)lesions,and adverse reactions were compared between the 2 groups.Results:A reduction in BCVA((0.57±0.15),(0.46±0.12)LogMAR,(0.55±0.13),(0.44±0.13)LogMAR)and CMT((256.27±24.58),(237.58±25.67)μm,(247.94±26.27),(232.49±27.29)μm)after 1 month and 3 month mon after treatment was detected in both groups(P<0.05).The BCVA and CMT at different time points yielded no statistical difference between the 2 groups(P>0.05).The total effective rate of CNV leakage treatment(85.96%vs 88.46%)and overall adverse reaction rate(19.29%vs 17.30%)demonstrated no statistical difference between the 2 groups(P>0.05).Conclusion:Both intravitreal injections of conbercept and that of aflibercept are effective in restoring retinal structure,reducing macular oedema,decreasing CNV leakage,and improving BCVA in patients with nAMD,with a low incidence of adverse effects and a good safety profile.
Keywords：Neovascular age-related macular degenerationConberceptAfliberceptBest corrected visual acuityAdverse reaction
Publication Date：2023-10-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 304-307 )